More than 600,000 Americans are expected to die of cancer this year, which translates to about 1,660 deaths per day.1 Approximately 40 out of 100 men and 39 out of 100 women will develop cancer during their lifetime.1
We recognize the incredible burden that cancer places on individuals and the people who care for them. Their stories motivate and inspire us in our mission to develop novel treatment options, expand access to therapies, provide patient support services and partner with patient organizations around the world to fully understand both patient and caregiver needs.
We are building on a rich legacy in oncology with a renewed commitment to advancing transformative therapies to help improve outcomes and impact the lives of people living with many different types of cancer.
Our oncology strategy focuses on building a portfolio of high-quality assets across skin, blood, breast and lung cancers, and centers on four anchor treatments that we believe have the potential to transform patient care.
Determined for patients around the world
Above from left to right: Bernard, multiple myeloma, France; Danielle, multiple myeloma, USA; John, prostate cancer, USA
Our approach to science
We are committed to translating scientific discoveries into potential new treatments and addressing critical gaps in care across a variety of cancers, including some of the most challenging types. Our breadth of scientific platforms and pragmatic approach to conducting both in-house research and partnering with companies across industry puts us in a position to select a promising tool for each target.
Taking advantage of our capabilities in multi-targeted biologics, nanobodies and small molecules, we aim to bring first-in-class and/or best-in-class treatment options for people struggling with difficult-to-treat cancers.
Our molecular research approaches include targeted therapeutics that aim to target genetic changes found in tumors but not normal cells, drugs that suppress hormone driven cancers and antibody-drug conjugates that utilize monoclonal antibodies to deliver cytotoxic anticancer drugs into tumors, minimizing systemic exposure and sparing normal tissues.
Our immuno-oncology research is focused on addressing the underlying mechanisms of resistance to immunotherapy. The goal of our research is to make tumors receptive to immune checkpoint inhibitor treatments, which can enable the immune system to attack tumor cells.
We are testing a wide range of drug combinations. Because tumors often mutate, simultaneous treatment with multiple therapies is a promising approach in addressing difficult-to-eradicate cancers.
We are proud of our high-quality and relevant services that help appropriate patients receive our medications and best manage living with cancer. We have engaged and partnered with key organizations to truly understand what our patients need and how we can support them.
- Our CareASSIST Patient Support Program can help provide reimbursement and financial assistance to eligible patients and help them identify additional resources for support. The program was developed specifically around the needs of people living with cancer and is a reminder that we continue to grow, adapt and change in order to meet the ongoing needs of our patients.
- Our Multiple Myeloma Journey Partners Program is a free, one-hour educational program that gives people with multiple myeloma and their caregivers an opportunity to hear a trained Journey Partner share his or her personal experience of living with multiple myeloma and having an autologous stem cell transplant. The program also provides helpful resources and highlights the importance of considering a transplant evaluation.
Learn about treatment options
1. American Cancer Society. Cancer Facts & Figures 2020. https://www.cancer.org/content/dam/cancerorg/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf, Accessed August 2020. Accessed August, 2020.
Our multiyear When Cancer Grows OldTM initiative is intended to address the challenges of cancer and aging. We are collaborating with the global cancer community of advocates, healthcare providers and others around the world to find solutions and create change so that aging patients with cancer have the best possible chance to grow old.